Eli Lilly has anted up for its next big bet on a next-gen pain drug, buying Hydra assets
With its new CGRP migraine drug Emgality (galcanezumab) OK’d a few months ago and more late-stage work underway on lasmiditan and
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
